Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 5Wilms Tumor 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Leukemia 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Xanthogranuloma, Juvenile 1Pancreatic Ductal Adenocarcinoma 1Myelodysplastic Syndromes 1Lymphoma, Follicular 1Histiocytic Sarcoma 1Chondrosarcoma 1Central Nervous System Neoplasms 1

Interventions

paricalcitol 1ivosidenib 1Taxes 1Neoadjuvant Therapy 1Losartan 1Hydroxychloroquine 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Pancreatic Ductal Adenocarcinoma × ivosidenib × Clear all
NCT05209074 2025-09-05

Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma

Case Comprehensive Cancer Center

Phase 1 Active not recruiting
16 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡